Chemotherapy News and Research

Latest Chemotherapy News and Research

Viruses to treat metastatic cancers

There exists a "type" of cancer that is common yet rarely discussed—metastatic cancer, or cancer that has spread from the part of the body where it originated (the primary tumor) to another (such as lungs, bones or liver). Although much research is being done to combat primary tumors, there still exists a crucial need to find a treatment that can be effective against metastatic cancer, or "mets." Could a virus be the answer that finally beats the mets?

15 Nov 2012

Fevers can be helpful as a child battles an illness

For many parents discovering their child has a fever can be unnerving. It's one of the most common reasons parents call their doctor or bring their child in for medical care. Fevers are just a natural part of many illnesses and, in fact, can be helpful as a child battles an illness.

15 Nov 2012

New gene delivery vehicle opens route to the heart of cells in solid tumors

There are plenty of effective anticancer agents around. The problem is that, very often, they cannot gain access to all the cells in solid tumors. A new gene delivery vehicle may provide a way of making tracks to the heart of the target.

15 Nov 2012

Adding bortezomib ‘boosts acute myeloid leukemia chemotherapy response’

Older patients with untreated acute myeloid leukemia may benefit from having bortezomib added to daunorubicin and cytarabine during induction therapy and to consolidation intermediate-dose cytarabine, the results of a US study indicate.

14 Nov 2012

EpiCept third quarter revenue increases to $0.9 million

EpiCept Corporation today reported a net loss for the three months ended September 30, 2012 of $1.1 million and a net loss for the nine months ended September 30, 2012 of $1.7 million.

14 Nov 2012

Tiltan Pharma initiates enrollment in TL-118 Phase 2 trial for metastatic pancreatic cancer

Tiltan Pharma Ltd. today announced that it has enrolled the first U.S. patient, at White Plains Hospital in Westchester County N.Y., in a Phase 2 clinical trial of its anti-angiogenic product, TL-118, for the treatment of metastatic pancreatic cancer.

14 Nov 2012

Reflexology can help cancer patients manage their symptoms and perform daily tasks

A study led by a Michigan State University researcher offers the strongest evidence yet that reflexology - a type of specialized foot massage practiced since the age of pharaohs - can help cancer patients manage their symptoms and perform daily tasks.

14 Nov 2012

Mayo Clinic receives FDA approval for Choline C 11 Injection to help detect prostate cancer

Mayo Clinic has received U.S. Food and Drug Administration approval to produce and administer Choline C 11 Injection, an imaging agent used during a positron emission tomography (PET) scan to help detect sites of recurrent prostate cancer. Mayo Clinic is the first, and currently only, institution in North America approved to produce this imaging agent.

9 Nov 2012

Plexxikon updates Zelboraf Phase 1 data on BRAF V600E mutation-positive melanoma

Plexxikon today announced that updated Phase 1 clinical data of Zelboraf (vemurafenib) were presented at the Society for Melanoma Research (SMR) 2012 Congress, held November 8-11 in Los Angeles, CA.

8 Nov 2012

Glycemic load raises colon cancer recurrence risk

Increased glycemic loads and high carbohydrate consumption may increase the risk for colon cancer recurrence, show the results of a US study.

8 Nov 2012

Oral verrucous lesions need special diagnostic attention

Care should be taken to diagnose oral verrucous lesions accurately according to their nature, behavior, and malignant potential, and should be differentiated from grade I squamous cell carcinoma, suggest Indian researchers.

8 Nov 2012

Many patients over-optimistic about palliative chemotherapy

A majority of advanced colorectal and lung cancer patients in the USA may not understand that chemotherapy is unlikely to cure them, according to the results of a study published in The New England Journal of Medicine.

8 Nov 2012

Canine lymphoma treatment adds up to cystitis

High cumulative doses of the alkylator cyclophosphamide could be to blame for the development of sterile hemorrhagic cystitis in dogs being treated for lymphoma, indicate the results of a US study.

8 Nov 2012

Synthetic cannabinoid could treat pain in diabetes patients

Oral synthetic cannabinoid nabilone may be effective for treating diabetic peripheral neuropathic pain, a study shows.

8 Nov 2012

Ethical issues in organ transplantation

The MacLean Center for Clinical Medical Ethics will focus its 24th Annual Dorothy J. MacLean Fellows Conference on ethical issues in organ transplantation and other broader ethical topics, including global health, pediatric immunization and end-of-life care.

8 Nov 2012

Carbohydrate-rich food intake may cause recurrence of colon cancer

Colon cancer survivors whose diet is heavy in complex sugars and carbohydrate-rich foods are far more likely to have a recurrence of the disease than are patients who eat a better balance of foods, a new study by Dana-Farber Cancer Institute researchers indicates.

8 Nov 2012

EpiCept, Immune Pharmaceuticals enter definitive merger agreement

Immune Pharmaceuticals Ltd., a privately held Israeli company, and EpiCept Corporation today announced that they have entered into a definitive merger agreement. The transaction is anticipated to close during the first quarter of 2013 and is subject to satisfaction of certain customary closing conditions, including the approval of a majority of EpiCept shareholders.

8 Nov 2012

Synta announces interim results from docetaxel Phase 2b/3 trial on NSCLC

Synta Pharmaceuticals Corp. announced today that interim results from the Phase 2b/3 GALAXY trial will be presented at the Chemotherapy Foundation Symposium in New York City on Friday, November 9 during the 11:45 a.m. session on new agents for lung cancer. Presenting this data at the conference will be Dr. Suresh Ramalingham, Professor, Hematology & Medical Oncology, and Director, Translational Thoracic Malignancies Program, of the Winship Cancer Institute of Emory University.

7 Nov 2012

Taiho Pharmaceutical announces early stage data for eight novel oncology compounds

Taiho Pharmaceutical Co., Ltd., the developer of the first orally available fluorouracil (FU) Chemotherapeutic treatment (TS-1/S-1), is presenting early stage data for eight novel oncology compounds, including potential first-in-class therapies.

7 Nov 2012

MASP-1 enzyme plays a central role in activating the complement system

Researchers from Aarhus University, Denmark, have now discovered an important mechanism behind one of our most fundamental lines of immune function. The discovery has been published in the esteemed scientific journal, The Journal of Immunology, where it has been highlighted as a top story.

7 Nov 2012